Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 10,510 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Endogenous Cushing's Syndrome
Interventions: Osilodrostat; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Experimental hyperglycemia; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Renal Cell Carcinoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 6 more

Conditions: Breast Cancer
Interventions: MRI Biopsy; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Ceralasertib, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • New Haven, Connecticut • Trumbull, Connecticut + 9 more

Conditions: Dyslipidemias, Obesity
Interventions: Milk Polar Lipid-Rich Dairy Powder, Dairy Powder; Drug · Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Femoral Neck Fractures, Intertrochanteric Fractures
Interventions: PENG, FICB; Procedure
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Jacksonville, Florida + 6 more

Conditions: Aging, Aging, Healthy, Aging Well, Aging, Biological
Interventions: Positive Emotion Skills Intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Liver Malignancy
Interventions: Yttrium-90, Selective Internal Radiation Therapy, Stereotactic Body Radiation Therapy; Device · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Huntington Disease, Parkinson Disease
Interventions: MindTrails-Movement, Waitlist Control; Behavioral · Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Blood tests, Inebilizumab; Other · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Detroit, Michigan • Houston, Texas

Conditions: Breast Inflammatory Carcinoma
Interventions: Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 214
States / cities: Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more

Conditions: Stroke
Interventions: Group Lifestyle Balance, Usual Care; Behavioral · Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Group B Streptococcal Infections
Interventions: IVT GBS-06, Placebo; Biological
Lead sponsor: Inventprise Inc.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Cancer
Interventions: Atezolizumab, Tobemstomig, Tiragolumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Multiple Myeloma, Amyloidosis
Interventions: Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant; Device · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Plasma Cell Myeloma Refractory
Interventions: Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Los Angeles, California • West Hollywood, California + 29 more

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Interventions: HBI-2376; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 11
States / cities: Duarte, California • Encinitas, California • Fullerton, California + 7 more

Conditions: Type 1 Interferonopathies
Interventions: BI 3000202_low dose, BI 3000202_high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Skin Laxity, Wrinkle, Skin Condition
Interventions: Profound Matrix; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Jacksonville, Florida • Marlborough, Massachusetts • Fayetteville, North Carolina + 1 more

Conditions: Mild Cognitive Impairment, Mild Dementia, Dementia Alzheimers, Dementia, Memory Impairment, NPS
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 65 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Bone Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), Stereotactic Linear Accelerator; Drug · Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Calcific Aortic Stenosis, Calcific Aortic Stenosis - Bicuspid Valve, Aortic Valve Disease, Aortic Valve Calcification, Aortic Diseases, Aortic Aneurysm, Aortic Valve Cusp Abnormality, Aortic Valve Disease Mixed, Aortic Valve Insufficiency
Interventions: Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 20 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Recurrent Hypoglycemia in Type 1 Diabetes (Aim 2)

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

PENG vs FICB for Hip Fracture in ED Patients

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Emotional Well-being and Measures of Healthy Aging

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Group Lifestyle Balance™ for Individuals With Stroke (GLB-CVA)

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

Assessing Cognitive Decline at Home

Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone

Identification of Genetic Causes of Calcific Aortic Valve Disease